Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Cost of Revenue: 2022-2025

Historic Cost of Revenue for Axsome Therapeutics (AXSM) over the last 3 years, with Sep 2025 value amounting to $11.9 million.

  • Axsome Therapeutics' Cost of Revenue rose 41.19% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.7 million, marking a year-over-year increase of 51.37%. This contributed to the annual value of $33.3 million for FY2024, which is 27.77% up from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Cost of Revenue is $11.9 million, which was down 11.42% from $13.4 million recorded in Q2 2025.
  • Axsome Therapeutics' Cost of Revenue's 5-year high stood at $13.4 million during Q2 2025, with a 5-year trough of $1.9 million in Q3 2022.
  • Moreover, its 3-year median value for Cost of Revenue was $8.1 million (2024), whereas its average is $8.6 million.
  • In the last 5 years, Axsome Therapeutics' Cost of Revenue soared by 239.50% in 2023 and then decreased by 16.66% in 2024.
  • Over the past 4 years, Axsome Therapeutics' Cost of Revenue (Quarterly) stood at $2.3 million in 2022, then skyrocketed by 222.04% to $7.4 million in 2023, then soared by 42.50% to $10.5 million in 2024, then skyrocketed by 41.19% to $11.9 million in 2025.
  • Its last three reported values are $11.9 million in Q3 2025, $13.4 million for Q2 2025, and $9.8 million during Q1 2025.